Allergen-specific immunotherapy for respiratory allergies: From meta-analysis to registration and beyond

Calderón, Moisés A.; Casale, Thomas B.; Togias, Alkis; Bousquet, Jean; Durham, Stephen R.; Demoly, Pascal

doi:10.1016/j.jaci.2010.08.024

Cited by 166 publications

(111 citation statements)

References 81 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…9,11 It has been well documented that atopic patients with Th2 profiles have a lower autoimmune disease risk than those patients in which a Th1 profile is predominant. 10,11 However, it appears that increasing IL-10 and TGF-B concentrations, as well as inducing lymphocyte tolerance and changes in the Th1/Th2 balance, could lead to autoimmune problems in patients after undergoing SIT. To assess the relationship between IgE-mediated allergies and autoimmune diseases from the perspective of a balanced profile of Th1/Th2 seems overly simplistic.…”

Section: Discussionmentioning

confidence: 99%

“…14,15 Data indicating that SIT might trigger the development of some autoimmune diseases, such as scleroderma, systemic vasculitis, multiple sclerosis and others, have been based on only a few reports. 4,[7][8][9][10][11] In addition, these diseases are relative contraindications for SIT in many international guidelines; however, there are no recommendations to preclude active patients with these diseases before SIT if they do not have any clinical disease symptoms. As a result, the studied patients had not undergone antibody assays prior to treatment, which undoubtedly limited the observations because the authors could not evaluate the dynamics of the changes in the tested antibodies during treatment.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The relationship between autoimmunity and specific immunotherapy for allergic diseases

Bożek

Kołodziejczyk²,

Bednarski

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

The aim of this study was to perform a 20-year post-specific immunotherapy (SIT) observational evaluation for an assessment of any manifestations of autoimmune disease or the appearance of autoantibodies in serum. In total, 1,888 patients (902 women and 986 men) were observed. The mean age of the patients was 34.1 §12.4 y at the start of the prospective observation after finishing SIT. New incidences of autoimmune disease and/or the presence of autoantibodies in serum were monitored. The SIT group was compared with control groups consisting of allergic patients who had very received SIT and with non-allergic subjects. There were no significant differences in the autoimmune disease prevalence between the allergic patients with or without SIT. However, significantly higher prevalence of 4 different autoimmune diseases (AID) were observed in the non-allergic patients during the same period. Additionally, the incidence of 8 different autoantibodies was significantly higher in non-allergic patients than in control subjects. Hashimoto disease was the most common autoimmune disease observed. The results of this longterm observational study indicated a lack of a significant prevalence of new instances of autoimmune disease during 20 y of observation post-SIT and at a rate lower than that of non-allergic control subjects, suggesting that SIT is safe in this regard in the long term.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The relationship between autoimmunity and specific immunotherapy for allergic diseases

Bożek

Kołodziejczyk²,

Bednarski

2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

show abstract

“…True mechanistic understanding of the effects of PIT necessitates assessment in the context of antigen-experienced, rather than naive, T cells, because the overriding aim of allergen immunotherapy is to combat established allergic immune responses (40). Previous work providing PIT between airway challenges suggested therapeutic benefit in experimental models in which allergenexperienced T cells should predominate (15).…”

Section: Discussionmentioning

confidence: 99%

“…Clinically, there is limited information on the activation status of T cells before, and after, immunotherapy, and there is no consensus as to the most efficacious means to deliver specific immunotherapy, including PIT, in terms of dose, route, and frequency (40,52). In light of this study, it is interesting to speculate on how currently favored regimes for delivering allergen immunotherapy, for example multidose regimes (17,20,53,54), affect the dynamics of CD62L expression of Th2 cells and hence their behavior in re- sponse to PIT.…”

Section: Discussionmentioning

confidence: 99%

Effector and central memory T helper 2 cells respond differently to peptide immunotherapy

Mackenzie

Nowakowska

Leech

et al. 2014

Proc. Natl. Acad. Sci. U.S.A.

View full text Add to dashboard Cite

Peptide immunotherapy (PIT) offers realistic prospects for the treatment of allergic diseases, including allergic asthma. Much is understood of the behavior of naive T cells in response to PIT. However, treatment of patients with ongoing allergic disease requires detailed understanding of the responses of allergenexperienced T cells. CD62L expression by allergen-experienced T cells corresponds to effector/effector memory (CD62L lo ) and central memory (CD62L hi ) subsets, which vary with allergen exposure (e.g., during, or out with, pollen season). The efficacy of PIT on different T helper 2 (Th2) cell memory populations is unknown. We developed a murine model of PIT in allergic airway inflammation (AAI) driven by adoptively transferred, traceable ovalbumin-experienced Th2 cells. PIT effectively suppressed AAI driven by unfractionated Th2 cells. Selective transfer of CD62L hi and CD62L lo Th2 cells revealed that these two populations behaved differently from one another and from previously characterized (early deletional) responses of naive CD4 + T cells to PIT. Most notably, allergen-reactive CD62L lo Th2 cells were long-lived within the lung after PIT, before allergen challenge, in contrast to CD62L hi Th2 cells. Despite this, PIT was most potent against CD62L lo Th2 cells in protecting from AAI, impairing their ability to produce Th2 cytokines, whereas this capacity was heightened in PIT-treated CD62L hi Th2 cells. We conclude that Th2 cells do not undergo an early deletional form of tolerance after PIT. Moreover, memory Th2 subsets respond differently to PIT. These findings have implications for the clinical translation of PIT in different allergic scenarios.

show abstract

“…Por lo tanto, el manejo de las enfermedades alérgicas respiratorias se centra en el uso de fármacos (antihistamínicos, esteroides inhalados o nasales, broncodilatadores) para controlar la inflamación de las vías respiratorias superiores e inferiores. Aunque estos tratamientos han demostrado ser efectivos y seguros, no ofrecen un beneficio duradero una vez suspendidos, y, además, no logran modificar el curso de la enfermedad (5).…”

unclassified

Impacto de la Inmunoterapia subcutánea con Dermatophagoides farinae y Dermatophagoides pteronyssinus sobre la calidad de vida de pacientes con rinitis y asma alérgica

et al. 2014

View full text Add to dashboard Cite

Contribución de los autores:Todos los autores participaron de igual forma en la atención de las pacientes, la recolección de los datos, la redacción y la corrección del manuscrito. Impacto de la inmunoterapia subcutánea conDermatophagoides farinae y Dermatophagoides pteronyssinus sobre la calidad de vida de pacientes con rinitis y asma alérgica Introducción. Como sucede en otras partes del mundo, la prevalencia de asma y rinitis alérgica en Colombia está en aumento. Se ha establecido que la inmunoterapia subcutánea con alérgenos es eficaz a largo plazo en pacientes con rinitis alérgica y asma sensibilizados a Dermophagoides. Objetivo. Proveer evidencia sobre los cambios relacionados con la calidad de vida inducidos por la inmunoterapia subcutánea en sujetos con alergia respiratoria. Materiales y métodos. Se seleccionaron 76 sujetos con diagnóstico de alergia respiratoria con sensibilización a Dermatophagoides farinae y Dermatophagoides pteronyssinus. Para la evaluación de la calidad de vida se emplearon los instrumentos Kidscreen-27 y SF-36 (Short form 36). Estos instrumentos se aplicaron en dos ocasiones: durante la primera visita, en la cual se iniciaba la inmunoterapia subcutánea, y un año después de haberse iniciado el tratamiento.Resultados. Al año de estar recibiendo la inmunoterapia, los 22 sujetos que completaron el estudio presentaron cambios positivos en términos de calidad de vida. En los niños, el principal cambio se presentó en el dominio del 'entorno escolar' mientras que en los adultos fue en el de la 'función física'. Discusión. Se evaluaron por primera vez en Colombia los beneficios inducidos por la inmunoterapia subcutánea para ácaros de polvo en la calidad de vida de sujetos con rinitis alérgica y asma mediante los cuestionarios Kidscreen-27 y SF-36. Los resultados proveen evidencia de que la inmunoterapia subcutánea influye positivamente en la calidad de vida en sujetos con rinitis asmática y asma sensibilizados a los ácaros de polvo. The impact of subcutaneous immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus on the quality of life of patients with allergic rhinitis and asthma Introduction: The prevalence of asthma and allergic rhinitis in Colombia is increasing at the same rate as it is in other parts of the world. It has been determined that allergen-specific subcutaneous immunotherapy is effective in subjects with allergic rhinitis and asthma that are sensitized to house dust mites: Dermatophagoides farinae and Dermatophagoides pteronyssinus. Objective: To provide evidence on changes in the quality of life of subjects induced by allergen-specific subcutaneous immunotherapy with Dermatophagoides farinae and Dermatophagoides pteronyssinus. Materials and methods:We selected 76 subjects with a diagnosis of respiratory allergy with sensitization to Dermatophagoides farinae and Dermatophagoides pteronyssinus. The instruments used for evaluating the quality of life were Kidscreen-27 and SF-36. These instruments were applied twice for each subject: once during the fir...

show abstract

Allergen-specific immunotherapy for respiratory allergies: From meta-analysis to registration and beyond

Cited by 166 publications

References 81 publications

The relationship between autoimmunity and specific immunotherapy for allergic diseases

The relationship between autoimmunity and specific immunotherapy for allergic diseases

Effector and central memory T helper 2 cells respond differently to peptide immunotherapy

Impacto de la Inmunoterapia subcutánea con Dermatophagoides farinae y Dermatophagoides pteronyssinus sobre la calidad de vida de pacientes con rinitis y asma alérgica

Contact Info

Product

Resources

About